Apogee Therapeutics Inc
APGEHealthcare|Biotechnology|USA
$133.65
+0.08 (+0.06%)
Tangible Book
$16.77
About
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Stock Price
+246.5%(1Y)
Pipeline Summary
8 total trials5
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
Active: 3Recruiting: 1Terminated: 1Completed: 1Withdrawn: 2
Active Trials (4)
An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
NCT07027527Atopic Dermatitis
Phase 1Active
Enrollment: 86 participants
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948Atopic Dermatitis
Phase 2Active
Enrollment: 470 participants
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT07003425Atopic Dermatitis
Phase 2Recruiting
Enrollment: 350 participants
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
NCT06920901Asthma
Phase 1Active
Enrollment: 31 participants
BioScore
4.6/10
Cautious
Ownership
Recent Insider Trades
HENDERSON MICHAEL THOMASSELL
2026-07-0820,000 shares @ $133.63
Dambkowski CarlSELL
2026-07-015,500 shares @ $132.74
Dambkowski CarlSELL
2026-06-2226,400 shares @ $132.6
HENDERSON MICHAEL THOMASSELL
2026-06-2280,000 shares @ $132.54
HENDERSON MICHAEL THOMASSELL
2026-06-1020,000 shares @ $83.38
Recent News
2026-07-11 02:00:32
2026-07-07 01:00:03
2026-07-06 19:00:05
2026-07-02 18:00:04
2026-06-25 18:00:05
Data last updated: Jul 12, 2026, 07:38 PM